C WorldWide Group Holding A S Grows Position in Boston Scientific Corporation $BSX

C WorldWide Group Holding A S grew its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 55.6% in the second quarter, HoldingsChannel.com reports. The fund owned 280,000 shares of the medical equipment provider’s stock after purchasing an additional 100,000 shares during the period. C WorldWide Group Holding A S’s holdings in Boston Scientific were worth $11,950,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. SVB Wealth LLC increased its position in shares of Boston Scientific by 62.3% in the second quarter. SVB Wealth LLC now owns 5,714 shares of the medical equipment provider’s stock worth $244,000 after purchasing an additional 2,193 shares during the last quarter. NewEdge Advisors LLC lifted its position in Boston Scientific by 3.2% during the second quarter. NewEdge Advisors LLC now owns 67,588 shares of the medical equipment provider’s stock valued at $2,885,000 after purchasing an additional 2,127 shares during the last quarter. IFP Advisors Inc grew its stake in Boston Scientific by 39.7% in the 2nd quarter. IFP Advisors Inc now owns 25,344 shares of the medical equipment provider’s stock worth $1,082,000 after buying an additional 7,196 shares in the last quarter. Arizona State Retirement System increased its holdings in shares of Boston Scientific by 1.5% in the 2nd quarter. Arizona State Retirement System now owns 412,385 shares of the medical equipment provider’s stock worth $17,601,000 after buying an additional 6,169 shares during the last quarter. Finally, Waverly Advisors LLC increased its holdings in shares of Boston Scientific by 1.0% in the 2nd quarter. Waverly Advisors LLC now owns 164,689 shares of the medical equipment provider’s stock worth $7,029,000 after buying an additional 1,700 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX stock opened at $45.00 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The firm has a market cap of $65.22 billion, a P/E ratio of 18.22, a P/E/G ratio of 1.10 and a beta of 0.57. The business’s 50 day moving average price is $47.04 and its 200-day moving average price is $55.18.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the company earned $0.75 earnings per share. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has approved a share buyback program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other news, Director David Habiger acquired 2,100 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the acquisition, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael Mahoney bought 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This represents a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. UBS Group decreased their price objective on Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Citigroup reduced their price target on Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Jefferies Financial Group lowered their price objective on Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, June 24th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Finally, Mizuho cut their target price on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific said manufacturing, shipping and other global operations are recovering, which could limit the disruption’s duration. The company also continues to point to multiple product launches and cost savings as potential longer-term growth drivers. Boston Scientific Says It Won’t Meet 2026 Guidance After Cyberattack
• Neutral Sentiment: The company has not provided replacement targets for its third-quarter or full-year 2026 outlook. Investors will likely focus on the pace of operational recovery and the size of the eventual revenue and profit shortfall. Boston Scientific says cyberattack likely to hurt 2026 sales, profit
• Negative Sentiment: The cyberattack disrupted manufacturing and order shipments worldwide, creating a material expected impact on third-quarter and full-year 2026 results. The warning raises the risk of lower sales, reduced operating leverage and an earnings miss relative to prior guidance. Boston Scientific Won’t Meet Guidance Due to Cyberattack
• Negative Sentiment: Beyond the immediate cyberattack effects, analysts noted pressure on Boston Scientific’s WATCHMAN and electrophysiology businesses, weakening the company’s 2026 growth outlook. That near-term uncertainty outweighs the longer-term benefit expected from new product launches and cost initiatives. Boston Scientific’s 2026 Growth Outlook Weakens

About Boston Scientific

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.